


# Overcoming the Study Conduct Challenges: Perspectives from EMMES, the LQOLCP Contract Research Organization

Keri Hammel, MS  
The EMMES Corporation  
October 19, 2014

# Financial Disclosure

- ▶ I have the following financial interests or relationships to disclose:
  - I am employed by The EMMES Corporation.
  - I have no additional financial disclosures.

# Outline

- ▶ Multiple Committees and Subcontractors
  - ▶ Agreement Execution
  - ▶ Study Conduct
    - Questionnaire Development
    - Site Selection
    - Data Collection
    - Monitoring
- 

# Multiple Committees

Steering  
Committee

Study  
Group

Administrative  
Operational  
Group

```
graph TD; SC[Steering Committee]; SG[Study Group]; AOG[Administrative Operational Group]; SG --- AOG;
```

The diagram illustrates the structure of multiple committees. It features three main components: a Steering Committee, a Study Group, and an Administrative Operational Group. The Steering Committee is positioned on the left. The Study Group is positioned on the right, and the Administrative Operational Group is positioned below it, connected by a vertical line that turns right at the bottom, indicating a reporting or support relationship.


# Multiple Committees

- Administrative Operational Group
  - Subcommittee of Study Group
  - Oversaw day-to-day operations
  - Met weekly since start of studies
- Steering Committee
  - 11 members
  - Membership from federal government, subject matter experts from professional organizations and patient representatives
  - Review study design, questionnaire content, accumulated data and related presentations/manuscripts
  - Met quarterly to finalize both protocols (EMMES or teleconference)
  - Met biannually during data collection and close-out of both studies

# Subcontractors

- ▶ The RAND Corporation
  - Cognitive Interviews
- ▶ Steve Reise
  - Psychometric Statistician
- ▶ Study Coordinator
  - PROWL-1 site
- ▶ PROWL-2 Clinical Sites
- ▶ Western IRB
  - PROWL-2 sites

# Agreement Execution

- ▶ Federal Inter–Agency Agreements
    - Navy and FDA
    - FDA and NEI
  
  - ▶ Steering Committee Agreements
    - Conflict of Interest forms
    - Confidential Disclosure Agreements
- 

# Study Conduct

## ▶ Questionnaire Development

- Platform selection – electronic data capture (EDC) vs. commercial survey software
- Content Development – Appropriate domains
- Cognitive Interviews – Provide feedback on questionnaire (e.g., remove or revise questions); provided feedback on embedded pictures (halos, glare, starbursts and double image)



# Study Conduct

## ▶ Site Selection

- PROWL-1
  - Navy
- PROWL-2
  - Request for Proposal
  - Ranking System to choose 5 sites
    - General clinical trials/studies experience
    - Recruitment and retention capability
    - Facilities
  - 5 Sites
    - 20/20 Institute (Indiana)
    - Durrie Vision (Kansas)
    - Johns Hopkins University (Maryland)
    - Stanford University (California)
    - Vance Thompson (South Dakota)

# Study Conduct

## ▶ Data Collection

- No paper forms – all data collected via EDC
- Challenges
  - Patient-reported outcomes data collection
    - Questionnaire completion – userID and passwords
      - No access to subject protected health information
      - Sealed envelopes
      - Forgotten passwords
    - Follow-up
      - Site follow-up with subjects
      - Daily automatic e-mails

# Study Conduct

- ▶ Enrollment Challenges
  - PROWL-1
    - Deployment
    - Female Enrichment
  - PROWL-2
    - High Myopes and Hyperopes

# Study Conduct

## ▶ Monitoring

- Site Initiation Visits
- Interim and Close-out Monitoring
  - Remote (risk-based) Monitoring
  - FDA Guidance – Oversight of Clinical Investigations – A Risk-Based Approach to Monitoring (final August 2013) \*
    - Monitor data quality – Data Quality Reports
      - Missing data, protocol deviations, data trends
      - Site characteristics – performance measures
    - Randomly selected percentage of subjects to review during close-out
      - Skype – informed consent review
      - DocuBank – source document review

\*<http://www.fda.gov/downloads/Drugs/.../Guidances/UCM269919.pdf>

# Conclusion

- ▶ These studies were a testament to a collaborative and creative effort made by many to ensure the studies were completed in the most efficient manner.